دورية أكاديمية

Customized treatment for Parkinson’s disease: extending lifespan and improving symptoms

التفاصيل البيبلوغرافية
العنوان: Customized treatment for Parkinson’s disease: extending lifespan and improving symptoms
المؤلفون: Richa Indu, Sushil Chandra Dimri
المصدر: The Egyptian Journal of Neurology, Psychiatry and Neurosurgery, Vol 60, Iss 1, Pp 1-15 (2024)
بيانات النشر: SpringerOpen, 2024.
سنة النشر: 2024
المجموعة: LCC:Neurosciences. Biological psychiatry. Neuropsychiatry
مصطلحات موضوعية: Parkinson’s disease, Unified Parkinson’s Disease Rating Scale, Substantia Nigra, Dopamine, Levodopa, Hypomimia, Neurosciences. Biological psychiatry. Neuropsychiatry, RC321-571
الوصف: Abstract Background Parkinson's disease (PD) is the second most prevalent neurodegenerative ailment affecting aged people. Several motor and non-motor symptoms appearing with this disease are linked to reduction in dopamine levels. Parkinson’s disease manifested by a wide range of symptoms, including gait instability, voice impairments, bradykinesia, hypomimia, tremors, and cognitive dysfunctions, where the concern is its steady global progression. Therefore, by evaluating the stage-specific retention and transition thresholds, the suggested work attempts to detect the progression of PD. Similarly, the assessment of the annual rate of deterioration of symptoms aids in assessing the influence of medications on four stages and six prime symptoms. Results During the 9-year period following clinical diagnosis, a symptomatic deterioration of 34.995% is observed in untreated patients compared to treated patients. Furthermore, the experimental analysis illustrates that medicines assist in regulating only bradykinesia, tremors, hypomimia, and speech impairment, which lasts for 4.8 years on average. A saturation period is also identified during the moderate phase, where the computed average depreciation in the Unified Parkinson’s Disease Rating Scale (UPDRS) is the least. Similarly, from stages 1 to 4, medicines might improve stage retention by 4.44, 3.5, 2.72, and 1.6 years, respectively. It demonstrates that, despite transient advantages and adverse effects, medications also have an optimistic impact on PD patients. Conclusions Here, we show that medication can extend the lifespan of PD patients up to 12 years cumulatively. Furthermore, the proposed work suggests that stagewise alternative remedies for improving quality of life, boosting the benefits of medicines, and eliminating their side effects. These include counselling, diet changes, yoga asanas, herbal medicines, bio-cleansing and other therapies. The current work does not consider the temporary transition among stages; nonetheless, further investigation regarding PD could open avenues for more worthy treatments with fewer side effects.
نوع الوثيقة: article
وصف الملف: electronic resource
اللغة: English
تدمد: 1687-8329
Relation: https://doaj.org/toc/1687-8329
DOI: 10.1186/s41983-024-00844-6
URL الوصول: https://doaj.org/article/fc3d5c87c76c4ef6887dc01f25160469
رقم الأكسشن: edsdoj.fc3d5c87c76c4ef6887dc01f25160469
قاعدة البيانات: Directory of Open Access Journals
الوصف
تدمد:16878329
DOI:10.1186/s41983-024-00844-6